Ikaria Canada Inc.
340 Albert Street, Suite 1300
Ottawa, Ontario
K1R 7Y6

1 877 KNOW INO
background-science.jpg

IK-5001

« BACK
IK-5001 is a potential treatment for preventing cardiac remodelling and subsequent congestive heart failure following acute myocardial infarction.* ¹

Currently in a Phase I/II clinical trial, IK-5001 is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective “scaffold” that enhances the mechanical strength of the heart muscle during recovery and repair.

References
* In animal disease models.

  1. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117(11):1388-1396.